Quinupristin/dalfopristin, a new addition to the antimicrobial arsenal.
Johnson
A P
AP
Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, Colindale, London, UK.
Livermore
D M
DM
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003428:Cross Infection / Q000188:drug therapy* / Q000382:microbiology; D018432:Drug Resistance, Multiple; D016984:Enterococcus faecium / Q000187:drug effects; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D013211:Staphylococcus aureus / Q000187:drug effects; D013297:Streptococcus pyogenes / Q000187:drug effects; D006113:United Kingdom; D014769:Virginiamycin / Q000009:adverse effects / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D014769:Virginiamycin; C062940:quinupristin-dalfopristin